Affimed And BioNTech Immunotherapies Among Ones To Watch At AACR

Range Of New Modalities Put To Test

Affimed looks to build on the splash at last year’s American Association for Cancer Research meeting next month, while BioNTech aims to prove its immunotherapy capabilities with a CAR-T candidate.

Andrew Jackson Square in New Orleans, which hosts the first in-person AACR since 2019. • Source: Alamy

New data on a range of biologic immunotherapies and small-molecule cancer therapies will be presented at next month’s American Association for Cancer Research (AACR) congress, with updates from Affimed, BioNTech and AstraZeneca among the likely highlights.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Affimed And BioNTech Immunotherapies Among Ones To Watch At AACR

Range Of New Modalities Put To Test

Read the full article – start your free trial today!

More from Anticancer

More from Therapy Areas